Avery Therapeutics is a preclinical-stage company, developing advanced therapies for patients suffering from cardiovascular diseases, with the vision of being a leader in next-generation bioengineered therapeutics. Avery’s mission is to develop innovative treatments to address large unmet medical needs and improve human quality of life. Avery’s lead candidate is a tissue engineered cardiac graft, MyCardia™, in development for treatment of chronic heart failure.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):